Patient characteristics
. | Number . |
|---|---|
| Total no. of patients | 21 |
| Median age, y (range) | 54 (32-68) |
| Sex, M:F | 16:5 |
| Pts, transfusion dependent (%) | 16 (76) |
| Pts with Lille score more than 0 at tx (%) | 21 (100) |
| Marrow fibrosis grades III to IV (%) | 18 (90) |
| No. of pts with splenomegaly (%) | 16 (76) |
| No. of pts splenectomized (%) | 3 (14) |
| No. of pts untreated before tx (%) | 7 (33) |
| No. of pts treated; HU, IFN, steroids, danazol (%) | 14 (67) |
| Median time from dx to tx, mo (range) | 11 (1.5-168) |
. | Number . |
|---|---|
| Total no. of patients | 21 |
| Median age, y (range) | 54 (32-68) |
| Sex, M:F | 16:5 |
| Pts, transfusion dependent (%) | 16 (76) |
| Pts with Lille score more than 0 at tx (%) | 21 (100) |
| Marrow fibrosis grades III to IV (%) | 18 (90) |
| No. of pts with splenomegaly (%) | 16 (76) |
| No. of pts splenectomized (%) | 3 (14) |
| No. of pts untreated before tx (%) | 7 (33) |
| No. of pts treated; HU, IFN, steroids, danazol (%) | 14 (67) |
| Median time from dx to tx, mo (range) | 11 (1.5-168) |
Pts indicates patients; tx, transplantation; IFN, interferon; and dx, diagnosis.